AML

Published results from the PARADIGM study of azacitidine/venetoclax showed an event-free survival benefit and lower hemorrhage rates in acute myeloid leukemia.

A randomized comparison of ATG, PTCy, and a combination helped characterize the similarities and differences of these regimens used as GVHD prophylaxis in stem cell transplant.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Posttransplant revumenib maintenance in genetically defined AML shows promising survival and low relapse, with thrombocytopenia as key toxicity.

FDA grants orphan status to CLN‑049, an FLT3xCD3 T‑cell engager in phase 1, for relapsed/refractory patients with AML.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

Mipletamig plus venetoclax and azacitidine delivers high remission rates and no CRS in early RAINIER trial, boosting hopes for unfit AML patients.

Findings from the PARADIGM trial suggest that the use of azacitidine and venetoclax could replace intensive chemotherapy in younger, fit patients with acute myeloid leukemia.

A retrospective analysis showed 2-year survival outcomes of over 13,000 patients receiving allogeneic hematopoietic cell transplants by donor source.

The KOMET-007 trial reveals promising safety and efficacy of ziftomenib combined with venetoclax and azacitidine for relapsed/refractory AML patients.

A new combination therapy shows promising results in achieving durable remission for patients with NPM1-mutated acute myeloid leukemia.